[ad_1]
A team of US scientists is developing a promising approach to treating chronic kidney disease by regenerating damaged tissue with therapeutic cells.
By exploiting the unique characteristics of stem cells derived from human amniotic fluid, the research team of the Wake Forest Institute of Advanced Medicine (WFIR) in the United States has shown that cells can help restore the organ function in the preclinical model of a global patient.
"Our findings suggest that this type of stem cell can be used as a source of the global cell on the outside and can provide an alternative treatment strategy for patients with this chronic and debilitating disease," said James J. Bo, principal investigator at the institute.
According to the researchers, stem cells derived from amniotic fluid can be used as a global source of cells because they have the ability to become different types of cells and anti-inflammatories, making it a potential source of regeneration.
Unlike multi-functional stem cells and adults, stem cells derived from amniotic fluid probably do not trigger an immune response and are not at risk of tumor or ethical concerns.
For the current study, published in the March issue of Tissue Engineering, the research team discovered that stem cells living in amniotic fluid, injected into the preclinically diseased kidney, improved renal function based on measured levels of waste. After 10 years.
[ad_2]
Source link
